ENTA - Enanta Pharmaceuticals, Inc. EV/EBITDA Multiple

Corporate company logo of Enanta Pharmaceuticals, Inc. (ENTA)

The financial stability of Enanta Pharmaceuticals (ENTA) relies on royalties from key counterparties, although delays in new drug testing create risks for earnings. Development efficiency is enhanced by outsourcing research to external contractors while maintaining full patent ownership. The scientific division is based in Massachusetts, while production is handled by CDMO partners. The historical EV/EBITDA price action, which stands at 0.00, is clearly illustrated in the chart below.

ENTA Enanta Pharmaceuticals, Inc: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/14/2026

Analytical breakdowns for Enanta Pharmaceuticals

- stock price and consensus target price:
Stock Quotes Enanta|ENTA - Price Target Chart
- market capitalization statistics:
Market Capitalization Enanta Pharmaceuticals, Inc|ENTA - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Enanta Pharmaceuticals|ENTA - Accounting Value of Company|Market Cap to Net Assets Ratio enanta.com|ENTA - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Enanta Pharmaceuticals|ENTA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Enanta Pharmaceuticals, Inc.|ENTA - Company Cumulative Debt|Debt to Book Capitalization Ratio Enanta Pharmaceuticals, Inc|ENTA - Company Long-Term Indebtedness|Company Short-Term Debts Enanta Pharmaceuticals|Quick Liquidity enanta.com
- business earnings and investment ratios data:
ENTA - Company Profit|Future Profit Enanta Pharmaceuticals|ENTA - Market Price to Net Income Ratio|Forward P/E Multiple Enanta Pharmaceuticals|ENTA - PEG Multiple|Enterprise Value to EBITDA Ratio Enanta Pharmaceuticals, Inc|ENTA - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Enanta Pharmaceuticals|ENTA - Earnings per one share for the last 12 months|Quarterly EPS earnings growth enanta.com|ENTA - Earnings per share increase in current year|Earnings growth forecast for next year Enanta Pharmaceuticals
- company sales and revenue statistics:
ENTA - Revenue and Sales Volume|Company Projected Revenue Enanta|ENTA - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Enanta Pharmaceuticals, Inc
Initial company analysis:ENTA (Enanta)
Original product of enanta.com

The EV/EBITDA multiple compares the total enterprise value, including net debt, with its operating profit before taxes and amortization. By analyzing the EV/EBITDA valuation ratio over time, an investor determines the real value of assets relative to their ability to generate cash flow. An increase in this indicator may signal an overvaluation of shares or a decline in financial stability. For Enanta Pharmaceuticals (ENTA), stable royalties smooth out the metric's volatility during periods of costly clinical trials.

Competitor analysis for Enanta Pharmaceuticals

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio curevac.com CVAC|Valneva (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Biotechnology Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio SIGA|EV/EBITDA Multiple Emergent Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharmaceuticals (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio invivyd.com|EV/EBITDA Multiple INO (Inovio)|HilleVax Inc (HLVX) - Company Value to EBITDA|KLRS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|DYAI (Dyadic International) - Enterprise Value to Operating Income Before Depreciation|NNVC: EV/EBITDA Multiple|talphera.com (TLPH) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cocrystal Pharma|Enterprise Value to Operating Income Before Depreciation TRAW (Traws Therapeutics)|Enterprise Value to EBITDA Ratio DWTX (Dogwood Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio QLGN|EV/EBITDA Multiple ALVR (AlloVir)|EV/EBITDA Multiple VBI Vaccines, Inc. VBIV|VIRI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VXRT (Vaxart, Inc.)